Skip Navigation LinksHome > May 11, 2007 - Volume 21 - Issue 8 > Treatment interruptions predict resistance in HIV-positive i...
AIDS:
doi: 10.1097/QAD.0b013e32802e6bfa
Clinical Science

Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda

Oyugi, Jessica Ha; Byakika-Tusiime, Jayneb; Ragland, Kathleend; Laeyendecker, Olivere; Mugerwa, Royb; Kityo, Cissyc; Mugyenyi, Peterc; Quinn, Thomas Ce; Bangsberg, David Rd,f

Free Access
Article Outline
Collapse Box

Author Information

From the aInfectious Diseases Institute, Uganda

bMakerere University, Uganda

cJoint Clinical Research Centre, Kampala, Uganda

dEpidemiology and Prevention Interventions Center, Division of Infectious Diseases, Maryland

eJohns Hopkins University, Baltimore, Maryland

fPositive Health Program, San Francisco General Hospital, UCSF, San Francisco, California.

Received 3 February, 2006

Revised 22 August, 2006

Accepted 6 December, 2006

Correspondence to David R. Bangsberg, MD, MPH, Epidemiology and Prevention Interventions Center, POB 1372, UCSF, San Francisco, CA 94143-1372, USA. E-mail: db@epi-center.ucsf.edu

Collapse Box

Abstract

Objective: To evaluate adherence, treatment interruptions, and outcomes in patients purchasing antiretroviral fixed-dose combination (FDC) therapy.

Design: Ninety-seven participants were recruited into a prospective 24-week observational cohort study of HIV-positive, antiretroviral-naive individuals initiating self-pay Triomune or Maxivir therapy in Kampala, Uganda. Adherence was measured by monthly structured interview, unannounced home pill count, and electronic medication monitors (EMM). Treatment interruptions were measured as continuous intervals greater than 48 h without opening the EMM. The primary outcomes were survival with viral suppression below 400 copies/ml, CD4 cell increases, and genotypic drug resistance at 24 weeks.

Results: The median baseline CD4 cell count was 56 cells/μl and median log10 copies RNA/ml was 5.54; mean adherence ranged from 82 to 95% for all measures but declined significantly over time. In an intent-to-treat analysis, 70 (72%) patients had an undetectable plasma HIV-RNA level at week 24. Sixty-two of 95 (65%) individuals with continuous EMM data had a treatment interruption of greater than 48 h. Treatment interruptions accounted for 90% of missed doses. None of 33 participants who did not interrupt treatment for over 48 h had drug resistance, whereas eight of 62 (13%) participants who did interrupt therapy experienced drug resistance. Antiretroviral resistance was seen in 8% of individuals and overall mortality was 10% at 24 weeks.

Conclusion: HIV-positive individuals purchasing generic FDC antiretroviral therapy have high rates of adherence and viral suppression, low rates of antiretroviral resistance, and robust CD4 cell responses. Adherence is an important predictor of survival with full viral suppression. Treatment interruptions are an important predictor of drug resistance.

Back to Top | Article Outline

Introduction

Sub-Saharan Africa hosts more than 70% of the global burden of HIV infection, leading to 8000 HIV-related deaths a day [1]. In Uganda, as in many sub-Saharan African countries, generic fixed-dose combinations (FDC) with lamivudine, stavudine and nevirapine (prescribed as Triomune and Maxivir in Kampala, Uganda) is the first-line antiretroviral regimen. A recent report by Braitstein et al. [2] indicated that individuals on fully subsidized antiretroviral therapy (ART) have 0.23 less odds of death than patients on self-pay therapy. Estimates suggest that perhaps 1–2% of the 85 000 Ugandans currently on ART purchase generic FDC as Triomune or Maxivir [3]. Self-pay ART was a critical component of early treatment access, and remains a possible approach to accommodate universal access in the absence of donor funding to accommodate free treatment access for all.

We set out to evaluate adherence, immunological and virological treatment outcomes in ART treatment-naive HIV-infected Ugandans initiating self-pay antiretroviral treatment with either Triomune (Cipla Ltd., Mumbai, India manufactured stavudine, lamivudine and nevirapine) or Maxivir (manufactured by Cipla Ltd., and distributed by Okasa Pharmaceuticals Ltd., Vasodara, India). Adherence to therapy was measured by unannounced home pill counts, electronic medication monitoring (EMM; MEMS Track V, Aardex Ltd., Union City, California, USA), and patient report. Survival with viral suppression (plasma HIV-RNA levels < 400 copies/ml) was the primary outcome measure.

Back to Top | Article Outline

Methods

Eligibility and recruitment

Individuals initiating self-pay Triomune or Maxivir, at least 18 years of age, residing within 15 km of Kampala city center, and naive to combination HIV ART were recruited into a prospective observational study from pharmacies in Kampala, Uganda, between September 2002 and April 2004. During this time period, the vast majority of patients on ART in Uganda paid for these services. The cost of ART decreased from US$32 to US$17 per month during the study period. Participants received medical care from a variety of clinics in Kampala. As previously described, clients presenting prescriptions for generic ART were consecutively approached by a study research assistant to query interest in participating, assess eligibility criteria, and obtain informed consent [4]. Subsequent data collection including interview, adherence data collection, and phlebotomy was conducted during monthly home visits. All study procedures received ethical approval from Makerere University Faculty of Medicine, the Uganda National Council for Science and Technology, and the University of California San Francisco Institutional Review Board.

Back to Top | Article Outline

Data collection/procedures

Demographic information and psychometric measures

Demographic information and psychometric measures were collected during structured interviews upon enrollment, including the Beck Depression Inventory (BDI) [5,6], the Alcohol Use Disorders Identification Test [7], and the AIDS Clinical Trials Group symptom severity scale [8].

Back to Top | Article Outline
Adherence measurement

Adherence was assessed by EMM, monthly unannounced pill counts conducted at the participants' place of residence, monthly 3-day structured self-report, and monthly 30-day visual analog scale, as previously reported [4]. Participants' antiretroviral medication was placed in the electronic medication monitor upon enrollment. EMM adherence was calculated as one minus the number of pill bottle openings registered/number of doses prescribed between visits. Unannounced pill count was calculated as one minus the number of pills missing between counts/number of pills prescribed between counts. Three-day patient self-report was calculated as one minus the reported number of missed/doses prescribed over the previous 3 days. Thirty-day visual analog scale was estimated from the nearest 5% indicator that the participant marked on a visual analog scale. All adherence data were collected during unscheduled monthly home visits.

Back to Top | Article Outline
Treatment interruption and discontinuation

Treatment interruptions were defined as no recorded openings of the EMM cap for 48 h or longer. Individuals were considered to have discontinued therapy if they did not take any antiretroviral medications for 30 or more days.

Back to Top | Article Outline
Laboratory studies

Plasma HIV-RNA levels were obtained at baseline, 12 and 24 weeks using the Roche Amplicor assay (Roche Diagnostic Systems Ltd., Branchburg, New Jersey, USA), with a detection limit of 400 copies RNA/ml. CD4 cell count was obtained at baseline and 24 weeks using flow cytometry. Baseline CD4 cell counts were not repeated in patients with documented CD4 cell counts obtained by recognized laboratories within 3 months of treatment initiation. Participants with HIV-RNA levels above 1000 copies/ml at 12 or 24 weeks received genotypic resistance testing using the Trugene assay (Bayer Health Care LLC, Berkeley, California, USA) according to the manufacturer's protocol. Resistance to each antiretroviral medication was determined by entering genotypic changes in the Stanford Resistance Database [9]. Individuals with low, moderate, and high-level resistance were considered resistant for analyses.

Back to Top | Article Outline
Follow-up and retention

After recruitment, a research assistant transported the client home. A hand-drawn map with directions to the participants' residence was created to facilitate follow-up to the participant's home for subsequent data collection. The vehicle used at recruitment and at client follow-up was unmarked and carried no identifying information of the study's activities in attempts to preserve the confidential nature of the visits.

Back to Top | Article Outline
Statistical analysis

Descriptive statistics and survival rates are reported for the entire cohort. The mean adherence for the cohort is calculated from all available adherence data for each individual alive, active in follow-up, and on ART at 12 and 24 weeks (as treated). Symptoms/side effects are coded as any or none. The prevalence of viral load suppression and antiretroviral resistance was calculated for all individuals alive, active in follow-up, and on ART at 12 and 24 weeks (as treated), as well as for the entire enrolled cohort (intent-to-treat). We defined survival with viral suppression as enrolled in follow-up, alive, and with a viral load of 400 copies RNA/ml or less at 24 weeks. Logistic regression was used to assess predictors of adherence and survival with viral suppression of 400 copies or less at 24 weeks. All variables with P values of 0.25 or less in univariate analysis were included in the multivariate analysis. Items in the AIDS Clinical Trials Group symptom severity scale were coded as any or none. The chi-square test for trend was used to test associations between categorical variables. Based on the work of Spacek et al. [10], treatment interruptions defined as more than 48 h were used to evaluate the association between treatment interruptions and the risk of resistance. Pearson's correlation coefficient was used to assess the association between adherence and CD4 cell increase at 24 weeks. Adherence at 12 and 24 weeks were compared using a t-test for the difference between 24 and 12 weeks. All data were analysed using the SAS statistical analysis software (SAS Institute, Cary, North Carolina, USA).

Back to Top | Article Outline

Results

Recruitment

A total of 210 individuals were approached for this study. Ninety individuals were excluded because they resided beyond 15 km from Kampala city center. Ten individuals were excluded because they reported previous antiretroviral drug exposure. Six individuals were unable to provide informed consent because of altered mental status. Of 104 eligible individuals, seven (6.7%) declined participation (four people reported being ‘too busy’ and three reported concerns about HIV disclosure) for a total of 97 individuals enrolled. None of the enrolled individuals had received nevirapine as prevention of mother to child transmission or other previous ART.

Back to Top | Article Outline
Demographics and descriptive data at enrollment

Participants initiated therapy at advanced stages of HIV infection with a median CD4 cell count of 56 cells/μl [interquartile range (IQR) ± 130] and median log10 copies RNA/ml of 5.53 (IQR ± 5.76). The majority of the cohort was of Baganda ethnicity (the predominant clan in Kampala district) and female. The mean age was 36 years. Nearly one-quarter of participants were unemployed and paid for therapy by transfers (borrowing money) from other family members or friends. One third of the study participants had completed up to a primary level of education (Table 1).

Table 1
Table 1
Image Tools
Back to Top | Article Outline
Survival and retention

Of the 97 participants enrolled, 10 (10%) died during 24 weeks of follow-up. The mean time to death was 49 days (SD ± 32) days. Five of these participants (50%) died before the second monthly home visit. One participant died as a result of nevirapine-induced hepatotoxicity according to the clinical impression of the treating clinician. The remaining deaths were consistent with complications of advanced AIDS. One participant was lost to follow-up before the second monthly visit because of emigration. After the loss of these 11 patients, the remaining 86 participants had at least 24 weeks of follow-up.

Back to Top | Article Outline
Adherence

The mean levels of adherence across all measures ranged from 82 to 95% [self-report (93% at 12 weeks and 91% at 24 weeks), 30-day visual analog scale (95% at 12 weeks and 90% at 24 weeks), pill count adherence (90% at 12 weeks and 87% at 24 weeks) and EMM (91% at 12 weeks and 82% at 24 weeks)]. Adherence at 24 weeks was significantly lower than at 12 weeks for 3-day self-report (P = 0.044), 30-day visual analog scale (P = 0.008), pill count (P = 0.002), and EMM (P = < 0.001; Table 2). We did not identify significant predictors of adherence in multivariable analyses including sex, marital status, age, education, employment status, ethnicity, depression, alcohol use, symptom/side-effect severity, household size, income, source of antiretroviral payment, baseline viral load, and baseline CD4 cell count.

Table 2
Table 2
Image Tools
Back to Top | Article Outline
Antiretroviral discontinuation and interruption

Seventy participants received FDC ART for 24 weeks. Fourteen participants discontinued or modified therapy by 24 weeks (five switched to a new regimen, six developed tuberculosis and discontinued therapy, two chose to discontinue therapy because of a lack of belief in the drugs, and one discontinued treatment as a result of debilitating peripheral neuropathy). Two died 30 days or more after discontinuing therapy and six individuals re-initiated therapy after a mean discontinuation period of 43.5 days.

Of 95 individuals with continuous EMM data (one was lost to follow-up and one participant had a malfunctioning EMM device), 62 participants (65%) had interruptions of 48 h or greater. On average, there were 2.0 (SD 2.9) interruptions per participant; the average duration for each treatment interruption was 11 days (SD 9.2 days; Table 3). Ninety per cent of all missed doses occurred during a treatment interruption. Forty per cent (25/62) of individuals with treatment interruptions cited financial difficulty obtaining medication during interviews compared with 15% (5/33) of those without interruptions (χ2 6.32; P = 0.02). Otherwise, demographic characteristics, self-reported income, household size, depression, symptom/side-effect severity and alcohol use were not independently associated with treatment interruptions in multivariable analyses.

Table 3
Table 3
Image Tools
Back to Top | Article Outline
Client-reported symptom severity

At any time during the 6 months of study follow-up, 33% of participants reported severe symptoms and 73.7% reported moderate to severe symptoms. Cough (68.4%), symptom-defined peripheral neuropathy (65.3%), and self-reported skin rash (69.5%) were the most commonly described symptoms.

Back to Top | Article Outline
Virological and immunological response

The proportion of participants with plasma HIV-RNA levels of 400 copies/ml or less was 81.4% (70/86) and 72.2% (70/97) at 24 weeks for the as-treated and intent-to-treat analyses, respectively. The mean CD4 cell count increase was 116 cells/ml at 24 weeks. At week 24, the proportion of subjects with a plasma HIV-RNA level varied by adherence (96, 84 and 67% of patients had undetectable HIV-RNA levels in the 90–100, 80–89, and 50–79% groups, respectively; Fig. 1). Mean adherence of 90% or greater during 24 weeks follow-up by pill count, visual analog scale and electronic monitoring was significantly associated with plasma HIV-RNA levels below 400 copies RNA/ml (P < 0.0419, P < 0.0237 and P < 0.0410, respectively). The CD4 lymphocyte count increase was also significantly associated with unannounced pill count adherence (P = 0.028).

Fig. 1
Fig. 1
Image Tools
Back to Top | Article Outline
Survival with viral suppression of 400 copies or less at 24 weeks

For the entire cohort in bivariate analyses, depressive symptoms indicated by a BDI score of 14 or greater [odds ratio (OR) 0.58; 95% confidence interval (CI) 0.23–1.44] and adherence of 90% or greater (OR 7.04; 95% CI 2.61–18.98) had a potential association (P < 0.25) with survival with viral load suppression of 400 copies or less at 24 weeks. Age, sex, pre-treatment viral load, pre-treatment CD4 cell count, and alcohol use were not associated with survival with viral suppression below 400 copies/ml. In multivariate analyses, only adherence (OR 10.75; 95% CI 3.37–34.10) was associated with survival with viral suppression of 400 copies or less.

Back to Top | Article Outline
Genotypic resistance

Genotypic resistance results were obtained for 18 of 19 individuals with a HIV viral loads greater than 1000 copies per ml. Eight individuals had genotypic evidence of antiretroviral drug resistance, corresponding to 8% of those enrolled and 9% among those remaining in follow-up at 24 weeks. All eight individuals had nevirapine resistance (all high level), five had lamivudine resistance (four high level, one intermediate), and three had stavudine resistance (one high level and two low level; Table 4). Additional pre-existing baseline polymorphisms, including M36I in protease and R211K and L214F in reverse transcriptase were also detected in the specimens studied. These polymorphisms are consistent with motifs seen in drug-naive protease and reverse transcriptase from untreated subtype A and D-infected subjects from Uganda [11].

Table 4
Table 4
Image Tools

None of 33 (0%) subjects with continuous treatment (no interruption ≥ 48 h) had drug resistance. This contrasts with eight of 62 subjects (13%) who interrupted therapy for more than 48 h and experienced drug resistance (P = 0.047).

Back to Top | Article Outline

Discussion

In this prospective study of urban Ugandan patients with advanced AIDS purchasing FDC ART, we found high rates of adherence and viral suppression. Treatment interruptions of more than 48 h, largely as a result of financial or structural barriers of securing treatment, explained 90% of all missed doses and predicted drug resistance. Mortality at 24 weeks was 10% and most deaths occurred shortly after treatment initiation, similar to previously reported results [12].

During our recruitment period between 2002 and 2004, self-pay ART was the mainstay of HIV treatment and preceded the rapid scale-up of donor-subsidized ART that has since occurred in Uganda. Consistent with other reports [4,13–15], adherence was much higher than generally seen in resource-rich settings [16–19]. Nonetheless, adherence declined significantly over 24 weeks. This decline may be related to difficulties in meeting increasing financial demands of therapy over time [20–22]. It is possible that adherence might decline further after 24 weeks of follow-up as health benefits plateau and long-term toxicities develop [23].

Treatment interruptions, documented by gaps in continuous electronic monitoring, were significantly associated with drug resistance. Parienti et al. [24] similarly found that patient-reported interruptions were associated with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance in a resource-rich setting, and Spacek et al. [10] found that patient-reported treatment interruptions was associated with virological failure in Uganda. The long half-life of NNRTI may lead to effective monotherapy during a treatment interruption. This may be relevant particularly in individuals of African descent who have single nucleotide polymorphisms associated with decreased NNRTI clearance [25–27]. Byakika-Tusiime et al. [20] found that treatment interruptions were associated with financial barriers of securing therapy and competing family financial demands such as children's school fees and funeral costs for relatives. These interruptions in treatment, leading to virological rebound and drug resistance, may explain the elevated mortality risk observed for patients on self-pay therapy in resource-limited settings [2].

Additional treatment interruptions were related to disruptions in drug supply. At one point during the study, confusion between Uganda customs authorities and the National Drug Authority prevented the proper clearance of Triomune from Entebbe International Airport. This resulted in a nationwide shortage and a lack of treatment for individuals picking up refills over a 2-week period. Similar reported shortage of medications and financial constraints were important barriers to sustained self-pay therapy in Malawi [28].

We previously suggested that financial and logistical barriers to drug access, such as these, should not be considered non-adherence because adherence to therapy presumes access to therapy [20,21,23]. These results suggest that steady and reliable access to medications, in order to avoid treatment interruptions, will be critical to limiting the development of drug resistance in resource-limited settings.

Whereas adherence was closely associated with viral suppression, reliable viral suppression occurred at levels of adherence less than the commonly referenced 95% goal [17]. Eighty-four per cent of individuals were suppressed at 80–90% adherence and 67% of individuals were suppressed at 50–79% adherence. These high rates of viral suppression are probably a result of the combination of an antiretroviral-naive population receiving a potent antiretroviral regimen. Early studies of adherence and viral suppression in resource-rich environments were conducted in largely treatment-experienced populations with partly suppressive regimens. Although we advocate the highest adherence possible to maximize the probability of viral suppression, more potent regimens, including NNRTI, are capable of better viral suppression at moderate (80–90%) adherence [29,30].

We were unable to detect statistically significant predictors of adherence because of the relatively narrow range of adherence and the small sample. Self-reported income, an insensitive measure of household socioeconomic status in resource-limited settings [31], was not associated with either adherence or treatment interruptions, although financial challenges securing therapy were the most commonly cited reasons for treatment interruptions.

There are several limitations to our study. It is possible that the home visits may have affected adherence behavior. We have, however, been unable to detect an association between receipts of home visits and improved viral suppression in previous studies [32]. Although we found that treatment interruptions of greater than 48 h were associated with drug resistance, we did not have sufficient power to control for potential confounders. Whereas patients frequently reported HIV-related symptoms, including cough, neuropathy and rash, we could not distinguish whether these symptoms existed before antiretroviral treatment and were unrelated to medications. Finally, our results may not be generalizable to rural settings that comprise nearly 90% of Uganda's population or current urban treatment settings. The generalizability of our results is also limited because HIV treatment access in Uganda has changed significantly since this study with the expansion of free ART access provided by donor programmes.

In conclusion, we found that individuals purchasing generic HIV ART had high levels of adherence and viral suppression. Adherence was strongly associated with survival with viral suppression of less than 400 copies/ml at 24 weeks. Although participants demonstrated high levels of adherence, there was a significant decline over time. Treatment interruptions of more than 48 h, largely as a result of patient-reported financial challenges in securing self-pay therapy or interruptions in drug supply were an important predictor of drug resistance. These findings suggest that logistical interventions to ensure steady and reliable access to ART along with behavioral monitoring and support to sustain adherence will be important to minimize HIV drug resistance in resource-limited settings.

Back to Top | Article Outline

Acknowledgements

The authors would like to thank Dr Steven G. Deeks for comments on the manuscript as well as Annet Kawuma, Mary Kasango, and Irene Zawedde for participant recruitment, data collection and data management.

Sponsorship: This work was supported partly by the National Institutes of Health (NIMHRO-1 54907, NIMHRO-3 66654, NIAAA R-21 014784, NIAAA K-24 015287), the UCSF Center for AIDS Research (P30 MH59037), and the Doris Duke Charitable Foundation.

Back to Top | Article Outline

References

1. UNAIDS. Report of the global AIDS epidemic. Geneva: UNAIDS; 2006.

2. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817–824.

3. Lule F. Monitoring and evaluation, AIDS control program. Kampala, Uganda: Ministry of Health; 2006.

4. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, Mugyenyi P, Bangsberg DR. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 2004; 36:1100–1102.

5. Beck A, Ward C, Mendelson M. An inventory for measuring depression. Arch Psychiatry 1961; 4:561–567.

6. Richter P, Werner J, Heerlein A, Kraus A, Sauer H. On the validity of the Beck Depression Inventory. A review. Psychopathology 1998; 31:160–168.

7. Saunders J, Aasland O, Babor T, de la Fuente J, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption – II. Addiction 1993; 88:791–804.

8. Justice AC, Holmes W, Gifford AL, Rabeneck L, Zachin R, Sinclair G, et al, for the Adults AIDS Clinical Trials Unit Outomes Committee. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol 2001; 54(Suppl. 1):S77–S90.

9. Rhee S, Gonzales M, Kantor R, Betts B, Ravela J, Shafer R. HIV reverse transcriptase and sequence database. Nucl Acids Res 2003; 31:298–293.

10. Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis 2006; 42:252–259.

11. Becker-Pergola G, Kataaha P, Johnston-Dow L, Fung S, Jackson JB, Eshleman SH. Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults. AIDS Res Hum Retroviruses 2000; 16:807–813.

12. Laurent C, Ngom Gueye NF, Ndour CT, Gueye PM, Diouf M, Diakhate N, et al. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr 2005; 38:14–17.

13. Mills EJ, Nachega JB, Buchan I, Orbinski J, Altaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679–690.

14. Orrell C, Bangsberg D, Badri M, Wood R. Adherence is not a barrier to delivery of HIV antiretroviral therapy in resource-poor countries. AIDS 2003; 17:1369–1375.

15. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoue N, Bourgeois A, Calmy A, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004; 364:29–34.

16. Bangsberg DR, Deeks SG. Is average adherence to HIV antiretroviral therapy enough? J Gen Intern Med 2002; 17:812–813.

17. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21–30.

18. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001; 33:1417–1423.

19. Liu H, Golin CE, Miller LG, Hays RD, Beck K, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134:968–977.

20. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int J STD AIDS 2005; 16:38–41.

21. Crane JT, Kawuma A, Oyugi JH, Byakika JT, Moss A, Bourgois P, Bangsberg DR. The price of adherence: qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS Behav 2006; 10:437–442.

22. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006; 3:e438.

23. Bangsberg DR, Ware N, Simoni J. Adherence without access to antiretroviral therapy in sub-Saharan Africa. AIDS 2005; 20:140–141.

24. Parienti J, Massari V, Descamps D, Vabret A, Bouvet E, Larouze B, Verdon R. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38:1311–1316.

25. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunk WH, Eichelbaum M, et al. Genetic variability of CYP2B6 in population of African and Asian origin: allele frequencies, novel functional variants, and possible implication for anti-HIV therapy with efavirenz. Pharmacogenet Genom 2005; 15:861–872.

26. Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42:401–407.

27. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group Study. J Infect Dis 2005; 192:1931–1942.

28. Van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, Cleary PR, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health 2005; 10:464–470.

29. Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005; 40:158–163.

30. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43:939–941.

31. Oyugi J, Angemi D. Welfare assessment of Ugandans self-paying for generic antiretroviral therapy. In: XVth International AIDS Conference. Bangkok, Thailand, 11–16 July 2004 [Abstract ThPeE7936].

32. Wagner GJ, Ghosh-Dastidar B. Electronic monitoring: adherence assessment or intervention? HIV Clin Trials 2002; 3:45–51.

Cited By:

This article has been cited 58 time(s).

Jama Internal Medicine
Lifetime HIV Antiretroviral Therapy Adherence Intervention Timing Is Everything
Bangsberg, DR; Haberer, JE
Jama Internal Medicine, 173(4): 306-307.
10.1001/jamainternmed.2013.2858
CrossRef
Plos One
Predictors of Raised Viral Load during Antiretroviral Therapy in Patients with and without Prior Antiretroviral Use: A Cross-Sectional Study
Greig, JE; du Cros, PA; Mills, C; Ugwoeruchukwu, W; Etsetowaghan, A; Grillo, A; Tayo-Adetoro, A; Omiyale, K; Spelman, T; O'Brien, DP
Plos One, 8(8): -.
ARTN e71407
CrossRef
Plos One
HIV Drug Resistance Early Warning Indicators in Namibia for Public Health Action
Jonas, A; Gweshe, J; Siboleka, M; DeKlerk, M; Gawanab, M; Badi, A; Sumbi, V; Pereko, D; Blom, A; Mwinga, S; Jordan, MR; Jerger, L; Lau, K; Hong, SY
Plos One, 8(6): -.
ARTN e65653
CrossRef
Plos One
Medication Possession Ratio Associated with Short-Term Virologic Response in Individuals Initiating Antiretroviral Therapy in Namibia
Hong, SY; Jerger, L; Jonas, A; Badi, A; Cohen, S; Nachega, JB; Parienti, JJ; Tang, AM; Wanke, C; Terrin, N; Pereko, D; Blom, A; Trotter, AB; Jordan, MR
Plos One, 8(2): -.
ARTN e56307
CrossRef
AIDS and Behavior
Medication Persistence of HIV-infected Drug Users on Directly Administered Antiretroviral Therapy
Ing, EC; Bae, JW; Maru, DSR; Altice, FL
AIDS and Behavior, 17(1): 113-121.
10.1007/s10461-011-0082-0
CrossRef
Bulletin of the World Health Organization
Integrating antiretroviral therapy into antenatal care and maternal and child health settings: a systematic review and meta-analysis
Suthar, AB; Hoos, D; Beqiri, A; Lorenz-Dehne, K; McClure, C; Duncombe, C
Bulletin of the World Health Organization, 91(1): 46-56.
10.2471/BLT.12.107003
CrossRef
Expert Review of Anti-Infective Therapy
Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods
Marcellin, F; Spire, B; Carrieri, MP; Roux, P
Expert Review of Anti-Infective Therapy, 11(3): 239-250.
10.1586/ERI.13.8
CrossRef
Antiviral Therapy
The World Health Organization's global strategy for prevention and assessment of HIV drug resistance
Bennett, DE; Bertagnolio, S; Sutherland, D; Gilks, CF
Antiviral Therapy, 13(): 1-13.

Hiv Clinical Trials
Comparison of Nucleoside Reverse Transcriptase Inhibitor Use as Part of First-Line Therapy in a Serbian and a UK HIV Clinic
Dragovic, GJ; Smith, CJ; Jevtovic, DJ; Johnson, MA; Ranin, J; Salemovic, D; Youle, MS
Hiv Clinical Trials, 10(5): 306-313.
10.1310/hct1005-306
CrossRef
Annals of Internal Medicine
Spending More to Save More: Interventions to Promote Adherence
Bangsberg, DR; Deeks, SG
Annals of Internal Medicine, 152(1): 54-W13.

Journal of Antimicrobial Chemotherapy
Forgiveness of non-adherence to HIV-1 antiretroviral therapy
Shuter, J
Journal of Antimicrobial Chemotherapy, 61(4): 769-773.
10.1093/jac/dkn020
CrossRef
African Health Sciences
Psychological distress and adherence to highly active anti-retroviral therapy (HAART) in Uganda: A pilot study
Nakimuli-Mpungu, E; Mutamba, B; Othengo, M; Musisi, S
African Health Sciences, 9(): S2-S7.

Clinical Infectious Diseases
Average Adherence to Boosted Protease Inhibitor Therapy, rather than the Pattern of Missed Doses, as a Predictor of HIV RNA Replication
Parienti, JJ; Ragland, K; Lucht, F; de la Blanchardiere, A; Dargere, S; Yazdanpanah, Y; Dutheil, JJ; Perre, P; Verdon, R; Bangsberg, DR
Clinical Infectious Diseases, 50(8): 1192-1197.
10.1086/651419
CrossRef
Journal of Infectious Diseases
Two-Months-off, Four-Months-on Antiretroviral Regimen Increases the Risk of Resistance, Compared with Continuous Therapy: A Randomized Trial Involving West African Adults
Danel, C; Moh, R; Chaix, ML; Gabillard, D; Gnokoro, J; Diby, CJ; Toni, T; Dohoun, L; Rouzioux, C; Bissagnene, E; Salamon, R; Anglaret, X
Journal of Infectious Diseases, 199(1): 66-76.
10.1086/595298
CrossRef
Antiviral Therapy
Mortality and morbidity among HIV type-1-infected patients during the first 5 years of a multicountry HIV workplace programme in Africa
Van der Borght, SF; Clevenbergh, P; Rijckborst, H; Nsalou, P; Onyia, N; Lange, JM; de Wit, TFR; van der Loeff, MFS
Antiviral Therapy, 14(1): 63-74.

Hiv Medicine
Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme
Moore, DM; Zhang, W; Yip, B; Genebat, M; Lima, VD; Montaner, JSG; Hogg, RS
Hiv Medicine, 11(5): 299-307.
10.1111/j.1468-1293.2009.00779.x
CrossRef
Clinical Infectious Diseases
Highly active antiretroviral therapy (HAART)-plus: Next steps to enhance HAART in resource-limited areas?
Flanigan, TP; Wools-Kaloustain, K; Harwell, J; Cu-Uvin, S; Kimaiyo, S; Carter, EJ
Clinical Infectious Diseases, 45(): 1499-1501.
10.1086/522992
CrossRef
Lancet Infectious Diseases
Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review
Barth, RE; van der Loeff, MFS; Schuurman, R; Hoepelmon, AIM; Wensing, AMJ
Lancet Infectious Diseases, 10(3): 155-166.

Journal of Infectious Diseases
Preventing HIV antiretroviral resistance through better monitoring of treatment adherence
Bangsberg, DR
Journal of Infectious Diseases, 197(): S272-S278.
10.1086/533415
CrossRef
Bulletin of the World Health Organization
Antiretroviral therapy and early morality in South Africa
Boulle, A; Bock, P; Osler, M; Cohen, K; Channing, L; Hilderbrand, K; Mothibi, E; Zweigenthal, V; Slingers, N; Cloete, K; Abdullah, F
Bulletin of the World Health Organization, 86(9): 678-687.
10.2471/BLT.07.045294
CrossRef
British Medical Journal
Adherence to combination antiretroviral therapy in complex emergency settings
Jacob, ST; Abongomera, G
British Medical Journal, 338(): -.
ARTN a2662
CrossRef
AIDS Research and Human Retroviruses
Simple Adherence Assessments to Predict Virologic Failure among HIV-Infected Adults with Discordant Immunologic and Clinical Responses to Antiretroviral Therapy
Goldman, JD; Cantrell, RA; Mulenga, LB; Tambatamba, BC; Reid, SE; Levy, JW; Limbada, M; Taylor, A; Saag, MS; Vermund, SH; Stringer, JSA; Chi, BH
AIDS Research and Human Retroviruses, 24(8): 1031-1035.
10.1089/aid.2008.0035
CrossRef
British Medical Journal
Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda
Kiboneka, A; Nyatia, RJ; Nabiryo, C; Anema, A; Cooper, CL; Fernandes, KA; Montaner, JSG; Mills, EJ
British Medical Journal, 338(): -.
ARTN b201
CrossRef
Plos One
Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-Infected Ugandan Adults
Byakika-Tusiime, J; Chinn, LW; Oyugi, JH; Obua, C; Bangsberg, DR; Kroetz, DL
Plos One, 3(): -.
ARTN e3981
CrossRef
AIDS
Scaling up access to antiretroviral treatment for HIV infection: the impact of decentralization of healthcare delivery in Cameroon
Boyer, S; Eboko, F; Camara, M; Abe, C; Nguini, MEO; Koulla-Shiro, S; Moatti, JP
AIDS, 24(): S5-S15.

AIDS Patient Care and Stds
Rate and Predictors of Self-Chosen Drug Discontinuations in Highly Active Antiretroviral Therapy-Treated HIV-Positive Individuals
Murri, R; Guaraldi, G; Lupoli, P; Crisafulli, R; Marcotullio, S; von Schloesser, F; Wu, AW
AIDS Patient Care and Stds, 23(1): 35-39.
10.1089/apc.2007.0248
CrossRef
Clinical Infectious Diseases
Perspectives on Treatment Failure with Thymidine Analogue-based First-Line Regimens in Resource-Limited Settings
Riedel, DJ; Amoroso, A
Clinical Infectious Diseases, 49(): 1958-U198.
10.1086/648498
CrossRef
Sahara J-Journal of Social Aspects of Hiv-AIDS
Barriers and facilitators to patients' adherence to antiretroviral treatment in Zambia: a qualitative study
Sanjobo, N; Frich, JC; Fretheim, A
Sahara J-Journal of Social Aspects of Hiv-AIDS, 5(3): 136-143.

Clinical Infectious Diseases
Incidence and Predictors of Death, Retention, and Switch to Second-Line Regimens in Antiretroviral-Treated Patients in Sub-Saharan African Sites with Comprehensive Monitoring Availability
Palombi, L; Marazzi, MC; Guidotti, G; Germano, P; Buonomo, E; Scarcella, P; Altan, AD; Zimba, IDVM; Lio, MMS; De Luca, A
Clinical Infectious Diseases, 48(1): 115-122.
10.1086/593312
CrossRef
AIDS
Belief in divine healing can be a barrier to antiretroviral therapy adherence in Uganda
Wanyama, J; Castelnuovo, B; Wandera, B; Mwebaze, P; Kambugu, A; Bangsberg, DR; Kamya, MR
AIDS, 21(): 1486-1487.

Plos One
Not All Missed Doses Are the Same: Sustained NNRTI Treatment Interruptions Predict HIV Rebound at Low-to-Moderate Adherence Levels
Parienti, JJ; Das-Douglas, M; Massari, V; Guzman, D; Deeks, SG; Verdon, R; Bangsberg, DR
Plos One, 3(7): -.
ARTN e2783
CrossRef
Plos Medicine
A paradigm shift to prevent HIV drug resistance
Bangsberg, DR
Plos Medicine, 5(5): 695-696.
ARTN e111
CrossRef
AIDS
Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study
Parienti, JJ; Massari, V; Reliquet, V; Chaillot, F; Le Moal, G; Arvieux, C; Vabret, A; Verdon, R
AIDS, 21(): 2217-2222.

Annals of Internal Medicine
Association of Antiretroviral Therapy Adherence and Health Care Costs
Nachega, JB; Leisegang, R; Bishai, D; Nguyen, H; Hislop, M; Cleary, S; Regensberg, L; Maartens, G
Annals of Internal Medicine, 152(1): 18-W5.

Tropical Medicine & International Health
Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon
Sieleunou, I; Souleymanou, M; Schonenberger, AM; Menten, J; Boelaert, M
Tropical Medicine & International Health, 14(1): 36-43.
10.1111/j.1365-3156.2008.02183.x
CrossRef
Plos One
Food Insecurity as a Barrier to Sustained Antiretroviral Therapy Adherence in Uganda
Weiser, SD; Tuller, DM; Frongillo, EA; Senkungu, J; Mukiibi, N; Bangsberg, DR
Plos One, 5(4): -.
ARTN e10340
CrossRef
Plos One
Patient Retention and Adherence to Antiretrovirals in a Large Antiretroviral Therapy Program in Nigeria: A Longitudinal Analysis for Risk Factors
Charurat, M; Oyegunle, M; Benjamin, R; Habib, A; Eze, E; Ele, P; Ibanga, I; Ajayi, S; Eng, M; Mondal, P; Gebi, U; Iwu, E; Etiebet, MA; Abimiku, A; Dakum, P; Farley, J; Blattner, W
Plos One, 5(5): -.
ARTN e10584
CrossRef
Lancet
A wake-up call for global access to salvage HIV drug regimens
Mills, E; Nachega, JB
Lancet, 370(): 1885-1887.

Harm Reduction Journal
Harm reduction and equity of access to care for French prisoners: a review
Michel, L; Carrieri, MP; Wodak, A
Harm Reduction Journal, 5(): -.
ARTN 17
CrossRef
Tropical Medicine & International Health
Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaounde, Cameroon (EVAL survey, ANRS 12-116)
Marcellin, F; Boyer, S; Protopopescu, C; Dia, A; Ongolo-Zogo, P; Koulla-Shiro, S; Abega, SC; Abe, C; Moatti, JP; Spire, B; Carrieri, MP
Tropical Medicine & International Health, 13(): 1470-1478.
10.1111/j.1365-3156.2008.02170.x
CrossRef
Plos Medicine
Explaining Adherence Success in Sub-Saharan Africa: An Ethnographic Study
Ware, NC; Idoko, J; Kaaya, S; Biraro, IA; Wyatt, MA; Agbaji, O; Chalamilla, G; Bangsberg, DR
Plos Medicine, 6(1): 39-47.
ARTN e1000011
CrossRef
Patient Preference and Adherence
Risk factors for suboptimal antiretroviral therapy adherence in HIV-infected adolescents in Gaborone, Botswana: a pilot cross-sectional study
Ndiaye, M; Nyasulu, P; Nguyen, H; Lowenthal, ED; Gross, R; Mills, EJ; Nachega, JB
Patient Preference and Adherence, 7(): 891-895.
10.2147/PPA.S47628
CrossRef
Bmc Infectious Diseases
Dynamic logistic regression model and population attributable fraction to investigate the association between adherence, missed visits and mortality: a study of HIV-infected adults surviving the first year of ART
Kiwuwa-Muyingo, S; Oja, H; Walker, AS; Ilmonen, P; Levin, J; Mambule, I; Reid, A; Mugyenyi, P; Todd, J
Bmc Infectious Diseases, 13(): -.
ARTN 395
CrossRef
AIDS Research and Human Retroviruses
HIV Type 1 Virological Response and Prevalence of HIV Type 1 Drug Resistance Among Patients Receiving Antiretroviral Therapy, Shandong, China
Zhang, J; Kang, DM; Lin, B; Sun, XG; Fu, JH; Bi, ZQ; Nkengasong, JN; Yang, CF
AIDS Research and Human Retroviruses, 28(): 1658-1665.
10.1089/aid.2012.0019
CrossRef
Plos One
Effects of Physical Tracing on Estimates of Loss to Follow-Up, Mortality and Retention in Low and Middle Income Country Antiretroviral Therapy Programs: A Systematic Review
McMahon, JH; Elliott, JH; Hong, SY; Bertagnolio, S; Jordan, MR
Plos One, 8(2): -.
ARTN e56047
CrossRef
Plos Medicine
Dissemination of Research Findings to Research Participants Living with HIV in Rural Uganda: Challenges and Rewards
Baylor, A; Muzoora, C; Bwana, M; Kembabazi, A; Haberer, JE; Matthews, LT; Tsai, AC; Hunt, PW; Martin, JN; Bangsberg, DR
Plos Medicine, 10(3): -.
ARTN e1001397
CrossRef
AIDS
Adherence to antiretroviral therapy in resource-limited settings: everything matters
Hawkins, C; Murphy, R
AIDS, 21(8): 1041-1042.
10.1097/QAD.0b013e3281900eb9
PDF (53) | CrossRef
AIDS
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance
Gardner, EM; Burman, WJ; Steiner, JF; Anderson, PL; Bangsberg, DR
AIDS, 23(9): 1035-1046.
10.1097/QAD.0b013e32832ba8ec
PDF (455) | CrossRef
AIDS
Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy
Nachega, JB; Chaisson, RE; Goliath, R; Efron, A; Chaudhary, MA; Ram, M; Morroni, C; Schoeman, H; Knowlton, AR; Maartens, G
AIDS, 24(9): 1273-1280.
10.1097/QAD.0b013e328339e20e
PDF (198) | CrossRef
AIDS
HIV epidemiology and the effects of antiviral therapy on long-term consequences
Quinn, TC
AIDS, 22(): S7-S12.
10.1097/01.aids.0000327510.68503.e8
PDF (129) | CrossRef
AIDS
Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults
Nachega, JB; Hislop, M; Dowdy, DW; Gallant, JE; Chaisson, RE; Regensberg, L; Maartens, G
AIDS, 22(16): 2117-2125.
10.1097/QAD.0b013e328310407e
PDF (208) | CrossRef
AIDS
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen
on behalf of the SMART study group, ; Fox, Z; Phillips, A; Cohen, C; Neuhaus, J; Baxter, J; Emery, S; Hirschel, B; Hullsiek, KH; Stephan, C; Lundgren, J
AIDS, 22(17): 2279-2289.
10.1097/QAD.0b013e328311d16f
PDF (200) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Characteristics and Outcomes of Adult Patients Lost to Follow-Up at an Antiretroviral Treatment Clinic in Johannesburg, South Africa
Dalal, RP; MacPhail, C; Mqhayi, M; Wing, J; Feldman, C; Chersich, MF; Venter, WD
JAIDS Journal of Acquired Immune Deficiency Syndromes, 47(1): 101-107.
10.1097/QAI.0b013e31815b833a
PDF (114) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Prevalence of Drug-Resistant HIV-1 in Rural Areas of Hubei Province in the People's Republic of China
Luo, M; Liu, H; Zhuang, K; Liu, L; Su, B; Yang, R; Tien, P; Zhang, L; Gui, X; Chen, Z
JAIDS Journal of Acquired Immune Deficiency Syndromes, 50(1): 1-8.
10.1097/QAI.0b013e31818ffcdc
PDF (389) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
The Achilles' Heel of HIV Treatment in Resource-Limited Settings
Bangsberg, DR
JAIDS Journal of Acquired Immune Deficiency Syndromes, 47(2): 266-267.
10.1097/QAI.0b013e31815b2142
PDF (161) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Patterns of Individual and Population-Level Adherence to Antiretroviral Therapy and Risk Factors for Poor Adherence in the First Year of the DART Trial in Uganda and Zimbabwe
Muyingo, SK; Walker, AS; Reid, A; Munderi, P; Gibb, DM; Ssali, F; Levin, J; Katabira, E; Gilks, C; Todd, J; the DART Trial Team,
JAIDS Journal of Acquired Immune Deficiency Syndromes, 48(4): 468-475.
10.1097/QAI.0b013e31817dc3fd
PDF (200) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Short- and Long-Term Efficacy of Modified Directly Observed Antiretroviral Treatment in Mombasa, Kenya: A Randomized Trial
Kaai, S; Mandaliya, KN; Shikely, KS; Temmerman, M; Rutenberg, N; Sarna, A; Luchters, S; Geibel, S; Chersich, MF; Munyao, P
JAIDS Journal of Acquired Immune Deficiency Syndromes, 48(5): 611-619.
10.1097/QAI.0b013e3181806bf1
PDF (160) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Lower Risk of Resistance After Short-Course HAART Compared With Zidovudine/Single-Dose Nevirapine Used for Prevention of HIV-1 Mother-to-Child Transmission
Lehman, DA; Chung, MH; Mabuka, JM; John-Stewart, GC; Kiarie, J; Kinuthia, J; Overbaugh, J
JAIDS Journal of Acquired Immune Deficiency Syndromes, 51(5): 522-529.
10.1097/QAI.0b013e3181aa8a22
PDF (274) | CrossRef
Back to Top | Article Outline
Keywords:

Adherence; Africa; antiretroviral treatment; finances; fixed-dose combination; generic; HIV/AIDS; resistance; treatment interruptions

© 2007 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.